All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Bios Partners
Deal Size: $46.9 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 22, 2020
Details:
This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Varenicline Tartrate
Therapeutic Area: Ophthalmology Product Name: OC-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
The OLYMPIA Phase 2 trial aims to evaluate the safety and effectiveness of OC-01 nasal spray as compared to placebo for complete resolution of corneal staining in subjects with Stage 1 or Stage 2 NK in one or both eyes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI302
Therapeutic Area: Ophthalmology Product Name: IBI302
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The study demonstrated good safety and tolerability of IBI302. One week after administration, improved vision and reduction of retinal edema were observed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV.7m8-Aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2020
Details:
Adverum reported new interim data from the OPTIC trial that further demonstrate the transformative potential of ADVM-022 to greatly reduce the anti-VEGF injection burden for patients with wet AMD. ADVM-022 continues to maintain efficacy at both high and low doses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: OTX-TKI
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Company will present two posters and a paper at this year’s American Academy of Ophthalmology (AAO) that continue to highlight Ocular Therapeutix’s differentiated ophthalmology programs, including real world data on DEXTENZA® and new clinical data in OTX-TKI.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): THR-687
Therapeutic Area: Ophthalmology Product Name: THR-687
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
THR-687 is a potential best-in-class small molecule pan-RGD integrin antagonist being developed to treat DME holding potential of becoming the standard of care for DME patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Xalatan
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: ST266
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
Dr. Brown will discuss the development of Noveome’s neuroprotective program which is evaluating intranasal “nose-to-brain” delivery of its novel platform biologic, ST266, to treat traumatic brain injury and optic nerve/retinal diseases and injuries.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ST266
Therapeutic Area: Ophthalmology Product Name: ST266
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
New, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV.7m8-Aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
The abstract will showcase, Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial Cohorts 1-4).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
